SavedAdd your journal

Journals / Van Tıp Dergisi / 2007 / Cilt: 14 - Sayı: 4

Prophylactic dantrolene administration in a case of progressive musculary dystrophia with malignant hyperthermia risk

Malign hipertermi riski olan progresif musküler distrofili olguda profilaktik dantrolen uygulaması

Efetürk Ebru EKMEKÇİOĞLU
Cüneyit AKSU
BELGİN AKAN
Demet ALBAYRAK
Nermin GÖĞÜŞ
Pages
117–119
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present anaesthetic maintanence and Dantrolene prophylaxis in this particular PMD case who underwent a surgical precedure under general anaesthesia., .

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Progresnine museuloey dysisophy (PMD) is a congenital and progressive disease which usually starts in childhood.
📊
Key Findings & Data:For these patients, many surgical procedures might be necessary in the management of extremity sequels.
💡
Conclusion & Impact:We present anaesthetic maintanence and Dantrolene prophylaxis in this particular PMD case who underwent a surgical precedure under general anaesthesia., .
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Progresnine museuloey dysisophy (PMD) is a congenital and progressive disease which usually starts in childhood. For these patients, many surgical procedures might be necessary in the management of extremity sequels. Like the other muscular diseases, there is a high risk of MH in PMD. We present anaesthetic maintanence and Dantrolene prophylaxis in this particular PMD case who underwent a surgical precedure under general anaesthesia., .

Özet

Progresif musküler distrofi (PMD) genellikle çocukluk çağında başlangıç gösteren kalıtsal ve ilerleyici bir hastalıktır. Bu hastalıkta ekstremitelerdeki sekellerin düzeltilmesi için sık cerrahi müdahale gerekebilmektedir. Diğer kas hastalıklarında olduğu gibi PMD’de de artmış malign hipertermi (MH) riski vardır. Biz, bu olguda genel anestezi ile ameliyatı planlanan PMD’li bir hastada, MH riskine karşı uygulanan dantrolen profilaksisi ve anestezi takibi ile ilgili deneyimlerimizi sunduk.

🔖

Cite This Article

EKMEKÇİOĞLU, E. E., AKSU, C., AKAN, B., ALBAYRAK, D., GÖĞÜŞ, N. (2007). Prophylactic dantrolene administration in a case of progressive musculary dystrophia with malignant hyperthermia risk. Van Tıp Dergisi, Cilt: 14 - Sayı: 4, 117–119. https://ajindex.com/articles/334225

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Tunçbay T, Tunçbay E: Musküler Distrofiler: Nöromüsküler Hastalıklar. İzmir, Nobel Tıp Kitabevi, 418-497, 2004
  2. Kanagawa M, Toda T: The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis. J Hum Genet 51: 915-926, 2006
  3. Gronert GA, Antognini JF, Pessah IN: Malignant Hyperthermia in: Miller RD Anesthesia 5th edition. NewYork Churchill Livingstone; pg:1033-19,2000
  4. Larach Mg, Locallia AR, Allen GC et al: A clinical grading scala to predict malignant hyperthermia suspeptibility. Anesthesiology 80:771-775, 1994
  5. Halliday NJ: Malignant hyperthermia. J Craniofac Surg Sep 14:800-802, 2003
  6. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolen-a review of its pharmacology, therapeutic use and new development. Anaesthesia 59:364-373, 2004
  7. Gerbershagen MU, Fiege M, Krause T, Agarwal K, Wappler F: Dantrolene. Pharmacological and therapeutic aspects. Anaesthesist 52:238-245, 2003
  8. Podranski T, Bouillon T, Schumacker PM,et al: Compartmental pharmacokinetics of dantrolene in adults: Do malignant hyperthermia association dosing guidelines work. Anesth Analg 101:1695-1699, 2005
  9. Yousef MA, Vaida S, Somri M,et al: Changes in creatine phosphokinase consentrations after minor and major surgeries in children. Br J Anaesth 96:786-789, 2006
  10. Antognini JF: Creatine kinase alterations after acute malignant hyperthermia episodes and common surgical procedures. Anesth Analg 81:1039-1042, 1995
  11. Bernhardt D: Transient normalisation of CK blood levels in patients susceptible to malignant hyperthermia by oral administration of dantrolene. Anaesthesist 31:248-252, 1982
  12. Büyükokuroğlu ME, Taysi S, Büyükavcı M, Bakan E: Prevention of acute adriamycin cardiotoxicity by dantrolene in rats. Hum Exp Toxicol 23:251-256, 2004
  13. Cohen IT, Kaplan R: Repeat episodes of severe muscle rigidity in a child receiving sevoflurane. Paediatr Anaesth 16:1077-1079, 2006
  14. Girshin M, Mukherjee J, Clowney R, et al: The postoperative cardiovascular arrest of a 5-year-old male: an initial presentation of Duchenne’s muscular dystrophy. Paediatr Anaesth 16:170-173, 2006
  15. Takahashi H, Shimokowa M, Sha K, et al: Sevoflurane can induce rhabdomyolysis in Duchenne’s muscular dystrophy. Masui, 51:190-192, 2002
  16. Yomosa H., Nakahashi K., Hayashi M., et al: General anesthesia with sevoflurane and vecuronium for patients with dystrophia myotonica and progressive muscular dystrophy. Masui 40:1730-1735, 1991.